Ryan Spencer: It’s unclear. Depends on how the market demand and how the markets evolve and how our individual collaborator’s products are utilized and the efforts they put beyond behind keeping up with the shifting landscape including stream managements. So obviously we’ll be supportive of our partners and their initiatives. We believe COVID vaccination will continue globally for the years to come and is an important product in the marketplace. And so we will be there to support them as needed.
Unidentified Analyst: All right. Thank you.
Operator: Thank you. One moment for next question, please. Our next question comes from the line of Roy Buchanan with Citizens JMP. Your line is now open.
Roy Buchanan: Hey, thanks for taking the questions. A couple of quick ones on the play. But are you going to announce the results of the non-human challenge trial and the Phase 2 at the same time later this year may. Can you remind me are you making any cell-mediated immunity assessments in the Phase 2? And do you think those might be important? Any thoughts on that? Thanks.
Ryan Spencer: I’ll take the first one and then I’ll ask Ron to follow up on the second. One of the things you have to realize with the study with funded by the DOD is this is data that has we had orbital or duty partners on the release — that data release. And so that has not been clarified yet on exactly what the opportunity will be to show that data and what form for either trial. So we need to basically complete the trials first roll in, will be able make some top line comments like we have in the past but we don’t have a data release plan across both trials together that will we will work to be able to provide as much clarity on how that program is progressing in partnership with the DoD. Primary endpoint is antibodies that Rob would you please read any other commentary you have around cell-mediated immunity in the play program?
Rob Janssen: Yes, the primary endpoint is looking at antibodies because that’s been that’s what DOD has used in previously. They’ve developed this vaccine on particularly with respect to looking at antibodies non-human primates and then applying those to humans. We aren’t looking at cell-mediated immune your T cells in our in this Phase 2 study.
Roy Buchanan: Thank you.
Operator: Thank you. At this time, I’d like to hand the conference back over to Mr. Ryan Spencer for closing remarks.
Ryan Spencer: Thank you, operator and thank you all for joining us today. We appreciate your interest in Dynavax. We’re excited about our recent accomplishments and the strength of our position overall. We look forward to updating you on our progress focused on protecting the world against infectious diseases. Operator, you may end the call.
Operator: Ladies and gentlemen, thank you for joining us today. And this concludes today’s conference call. You may now disconnect. Everyone have a wonderful day.
